SureNano Science starts FDA toxicology studies for diabetes drug GEP-44 Apr 24, 2026 08:09AM
SureNano Science Initiates FDA Stage GLP Toxicology and Pharmacology Studies for GLP GEP-44 and Enters Discussions to Acquire Ibogaine Formulation IP Portfolio Apr 24, 2026 08:00AM
SureNano Science Ltd. Acquires GlucaPharm Inc., Advancing Second-Generation FDA Pathway GLP-1 Drug Development Feb 23, 2026 09:00AM
SureNano Announces Stock Option Grant Dec 12, 2025 09:18AM
SureNano closes $1.25 million private placement financing Dec 10, 2025 09:02AM


Dec 10, 2025 09:00AM SureNano Announces Closing of $1,250,000 Private Placement
Nov 19, 2025 04:30PM SureNano Announces Non-Binding Letter of Intent to Negotiate Proposed Transaction of GlucaPharm Inc. for GLP-1 Drug Development
Nov 5, 2025 06:38PM SureNano announces private placement to raise up to $1.25 million
Nov 5, 2025 06:36PM SureNano Announces Private Placement
Sep 19, 2025 04:30PM SureNano Closes Financing
Aug 22, 2025 09:00AM SureNano Announces Funding, Debt Settlement and AGSM Results